Alembic Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on August 05, 2025.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals announced its Q1 FY26 results (quarter ended June 30, 2025) approved at the board meeting on August 5, 2025. On a consolidated basis, revenue from operations rose about 9.5% to Rs. 1,710.72 crore from Rs. 1,561.73 crore a year ago, while profit after tax grew roughly 14.6% to Rs. 154.38 crore (EPS Rs. 7.85 vs Rs. 6.84). Operating margin improved to 16.84% from 15.32%, and net profit margin widened to 9.02% from 8.61%. On a standalone basis, however, revenue was almost flat at Rs. 1,494.17 crore and profit after tax fell sharply to Rs. 103.52 crore from Rs. 176.19 crore, with standalone operating margin dropping to 14.83% from 19.96%. The statutory auditor (KC Mehta & Co LLP) issued an unqualified review report on both consolidated and standalone results.
Consolidated performance was healthy, showing mid-teens profit growth and margin expansion, which is positive for shareholders. The steep standalone profit decline, likely reflecting a tough comparison base from last year's strong quarter, may draw some investor attention but the consolidated picture remains the key driver for the stock.